Enhancing Molecular Insights for Improved Disease Management

USD 250

* Required Fields

USD 250


Be the first to review this product

This edition of the Genetic Technology TOE profiles about enhancing molecular insights for improved disease management. The TOE covers advanced genomic insights across pediatric healthcare, novel chimeric antigen receptor T cell (CAR-T) therapies garnering regulatory approval, new targets for Parkinson’s disease, and partnerships for the development of mRNA cancer vaccines. The corresponding clinical trials scenario for Axicabtagene Ciloleucel is depicted, along with industry interactions.

The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; sequencing technologies; and genetically altered animals and plants.

The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare.

Keywords: Enhanced molecular insights, improved disease management, genomic insights, pediatric healthcare, Chimeric Antigen Receptor T Cell (CAR-T) therapy, regulatory approval, Parkinson’s disease, mRNA cancer vaccine.

Table of Contents

Enhancing Molecular Insights for Improved Disease ManagementInnovations in Molecular Pathology and Genomic Technologies for Disease ManagementAdvancing Genomic Insights Across Pediatric Healthcare Kite’s Chimeric Antigen Receptor T Cell (CAR-T) Therapy Garners Regulatory ApprovalNovel Targets for Parkinson’s DiseaseGlobal Partnership for Development of mRNA Cancer VaccineClinical Trial Analysis and Industry InteractionsClinical Trial Summary for Axicabtagene CiloleucelClinical Trial Summary for Axicabtagene CiloleucelSummary of Key Contacts




Related Research

Release Date : 08-Dec-17

Region : Global

Release Date : 08-Dec-17

Region : Global

Release Date : 01-Dec-17

Region : Global

Release Date : 29-Nov-17

Region : Global

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.